Pharmacokinetic Study of CKD-810 and Taxotere to Treat Patient With Advanced Solid Cancer

NCT01019941 | Completed Phase 1

• 1 other identifier: CKD-810_PK_phase I
• Study Type: interventional
• Target: 44
• Locations: 1 country
• Sites: 7

Brief Summary

The purpose of this study is to evaluate safety and the pharmacokinetic characteristics of docetaxel between two docetaxel products in patients with advanced solid cancer.

Conditions

Advanced Solid Cancers

Keywords

Docetaxel; CKD-810; Taxotere inj.; Advanced Solid cancer; Pharmacokinetic evaluation

Outcome Measures

Primary Outcomes (1)

• Pharmacokinetics of CKD-810 and Taxotere inj.

  2 Cycles

Secondary Outcomes (1)

• Safety of CKD-810 and Taxotere inj.

  2 Cycles

Study Arms (2)

1st cycle:CKD-810 -> 2nd cycle:Taxotere inj.

OTHER

Drug: CKD-810, Taxotere inj.

1st cycle:Taxotere inj.-> 2nd cycle:CKD-810

OTHER

Drug: CKD-810, Taxotere inj.

Interventions

CKD-810, Taxotere inj. DRUG

Patients will receive docetaxel 75mg/㎡ on Day 1 of each cycle(1 cycle = 3 weeks) as a 1-hour IV infusion. At the 1st cycle, CKD-810 75mg/㎡ administered. If the hematologic or non-hematologic toxicity was not appeared when the 1st cycle intervention was finished, keep going the 2nd cycle intervention.

Also known as: Docetaxel anhydrous, Docetaxel

1st cycle:CKD-810 -> 2nd cycle:Taxotere inj.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patient is greater than 18 years of age
• Advanced solid tumor
• locally advanced or metastatic breast cancer which docetaxel alone therapy was adequate
• locally advanced or metastatic non-small cell lung cancer which docetaxel alone therapy was adequate
• locally advanced or metastatic other malignant tumor which docetaxel alone therapy was adequate
• Patient has a life expectancy of at least 3 months
• Patient has an Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2
• Absolute neutrophil count ≥ 1,500/㎣
• Platelet count ≥ 100,000/㎣
• Hemoglobin ≥ 9.0g/dL
• Total Bilirubin ≤ 1.5 X ULN
• Alkaline Phosphatase ≤ 2.5 X ULN
• AST/ALT ≤ 2.0 X ULN
• Serum creatinine ≤ 1.5 X ULN or Creatinine clearance ≥ 60mL/min(Cockcroft equation)
• Patients should voluntarily sign a written informed consent before study entry

You may not qualify if:

• If present, any active bacterial infection that have to parenteral antibiotic therapy. Patients may be included if their infection has resolved to totally or controlled state
• Brain metastasis with neurologic symptom
• History of unstable cardiac arrhythmia, congestive heart failure or myocardial infarction within 6 months
• Known to test positive for HIV or hepatitis B or C
• Use of inducers or inhibitors of CYP3A4 within 2 weeks prior to the first dose of study medication. (Patients may be included if the patients who need to intake the medication such as cimetidine was keep the same dose continuously at 1 cycle and 2 cycle)
• Peripheral neuropathy ≥ Grade 2
• known resistant or uncontrolled severe hypersensitivity to docetaxel
• History of hypersensitivity reaction to Polysorbate 80
• The female patients of pregnancy, breast feeding or childbearing potential. And the patients has not laboratory result or the result was a positive serum pregnancy test, also Patients (M/F) with reproductive potential not implementing adequate contraceptive measurements. (In case of menopausal women, keeping menopause at least 12 months. All sexually active male patients must agree to use adequate methods of birth control throughout the study)
• Administration of any other tumor therapy, including chemotherapy, radiotherapy, and immunotherapy within 4 weeks before the beginning of study treatment. Patients may be included if the radiotherapy was conducted to relieve symptoms and that symptoms recovered to grade 1
• treated with any investigational drugs within 4 weeks before the beginning of study treatment
• Must be treated concurrent administration of other anti-cancer medicine
• Not able to participate to the study, at the discretion of the investigator

Sponsors & Collaborators

• Chong Kun Dang Pharmaceutical: lead

Study Sites (7)

Gachon University Gil Hospital

Inchon, South Korea

Location

The Catholic university of KOREA, Seoul ST. Mary's Hospital

Seoul, South Korea

Location

The Korea University Anam Hospital

Seoul, South Korea

Location

Ajou University Hospital

Suwon, South Korea

Location

Dongsan Medical Center, Keimyung University

Taegu, South Korea

Location

Yeoungnam University Hospital

Taegu, South Korea

Location

Ulsan University Hospital

Ulsan, South Korea

Location

Related Publications (1)

• Cho EK, Park JY, Lee KH, Song HS, Min YJ, Kim YH, Kang JH. Open-label, randomized, single-dose, crossover study to evaluate the pharmacokinetics and safety differences between two docetaxel products, CKD-810 and Taxotere injection, in patients with advanced solid cancer. Cancer Chemother Pharmacol. 2014 Jan;73(1):9-16. doi: 10.1007/s00280-013-2264-0. Epub 2013 Dec 12.

  PMID: 24337589 DERIVED

MeSH Terms

Interventions

Docetaxel

Intervention Hierarchy (Ancestors)

Taxoids; Cyclodecanes; Cycloparaffins; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals; Diterpenes; Terpenes

Study Officials

• JH Kang

  The Catholic University of Korea

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY

Study Record Dates

• First Submitted: November 23, 2009
• First Posted: November 25, 2009
• Study Start: August 1, 2009
• Primary Completion: August 1, 2010
• Study Completion: December 1, 2010
• Last Updated: December 16, 2010

Record last verified: 2010-12

Locations

KR (7)